13.78
+0.44(+3.30%)
Currency In USD
| Previous Close | 13.34 |
| Open | 13.37 |
| Day High | 14.06 |
| Day Low | 13.02 |
| 52-Week High | 19.18 |
| 52-Week Low | 3.73 |
| Volume | 1.02M |
| Average Volume | 1.12M |
| Market Cap | 745.18M |
| PE | -2.8 |
| EPS | -4.92 |
| Moving Average 50 Days | 14.27 |
| Moving Average 200 Days | 8.83 |
| Change | 0.44 |
If you invested $1000 in uniQure N.V. (QURE) 10 years ago, it would be worth $542.52 as of March 14, 2025 at a share price of $13.78. Whereas If you bought $1000 worth of uniQure N.V. (QURE) shares 5 years ago, it would be worth $341.85 as of March 14, 2025 at a share price of $13.78.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
uniQure Announces Completion of Enrollment in the First Cohort and Favorable Recommendation from the Independent Data Monitoring Committee for its Phase I/IIa Clinical Trial of AMT-191 for the Treatment of Fabry Disease
GlobeNewswire Inc.
Feb 03, 2025 12:05 PM GMT
~ Independent Data Monitoring Committee recommends proceeding with dosing of second cohort after planned safety assessment ~ ~ Company expects to initiate enrollment of second dose cohort in the first quarter of 2025 ~ LEXINGTON, Mass. and AMSTERDAM,
uniQure Announces Favorable Recommendation from Independent Data Monitoring Committee for its Phase I/II EPISOD1 Clinical Trial of AMT-162 for the Treatment of SOD1-ALS
GlobeNewswire Inc.
Jan 30, 2025 12:37 PM GMT
~ Independent Data Monitoring Committee Recommends Proceeding with Dose Escalation After Planned Safety Assessment of First Dose Cohort ~ ~ Company Expects to Initiate Enrollment of Second Dose Cohort in the First Quarter of 2025 ~ LEXINGTON, Mass. a
uniQure Announces Pricing of its Public Offering
GlobeNewswire Inc.
Jan 08, 2025 12:05 PM GMT
LEXINGTON, Mass. and AMSTERDAM, Jan. 08, 2025 (GLOBE NEWSWIRE) -- uniQure N.V. (Nasdaq: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced the pricing of its underwritten